RxDoctor Payments Data

Candace Camelon

Family · Carson City, NVNPI 1316193287

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 51 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$228
  • Astellas Pharma US Inc$116
  • Amgen$91
  • Bioventus LLC$82
  • Pfizer$68
  • Merck$65
  • plus $352 from 14 others

What the payments were for

  • Food & beverage$1,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,001 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$37,944
Medicare patients
104
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$85,875
JardianceEmpagliflozin36$28,756
RybelsusSemaglutide15$16,213
FarxigaDapagliflozin Propanediol11$10,511
Bupropion XlBupropion Hcl39$299
Metformin Hcl ErMetformin Hcl79$289
Metformin Hcl40$188
Hydroxyzine Hcl12$170
Fluoxetine Hcl19$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$228$102,08886 claims
Boehringer IngelheimJardiance$31$28,75636 claims
AstraZenecaFarxiga$39$10,51111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.

Other family in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →